1) Tirzepatide, a new incretin therapy in type 2 diabetes. Weekly subcutaneous Tirzepatide,a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, was better than weekly subcutaneous Simaglutide in A1c lowering and weight reduction. Frías JP, et al. New England Journal of Medicine June 25, 2021. DOI: 10.1056/NEJMoa2107519
5) Imeglimin, a novel glucose-lowering agent, is effective and safe for patients with type 2 diabetes. Imeglimin works by improving mitochondrial function to enhance insulin sensitivity and glucose-mediated insulin secretion. In a phase 3 trial, the drug lowered HbA1c by 0.87% compared to placebo and adverse events were comparable to placebo. Dubourg J, et al. Diabetes Care 2021;44(4): 952-959.1